Menopause GSM Treatment Updates: Beyond Hormone Therapy

Introduction

Genitourinary Syndrome of Menopause (GSM) affects over half of postmenopausal women, causing symptoms from vaginal dryness to urinary incontinence. As women may spend a third of their lives postmenopause, effective long-term management is essential. New research is expanding the treatment horizon beyond traditional hormone therapies.

Photobiomodulation Emerges as a Non-Hormonal Contender

A clinical trial led by researcher S.R.D.S. Pereira at Universidade Nove de Julho provides evidence for a novel approach. In the study, 65 postmenopausal women with GSM received either real photobiomodulation (PBM) therapy or a placebo treatment. The PBM protocol involved four weekly sessions applying an 808 nm laser to eight points around the vaginal opening.

The results, published in Climacteric, were specific. Women in the PBM group experienced a measurable reduction in urinary loss, scoring better on the International Consultation on Incontinence Questionnaire. They also reported subjective improvements in vaginal dryness and burning. However, the therapy did not produce significant changes in pelvic floor pressure or sexual function scores compared to placebo.

PBM, sometimes called low-level laser therapy, works by using specific wavelengths of light to stimulate cellular energy production. The researchers propose the 808 nm wavelength penetrates tissue to reach underlying structures, enhancing mitochondrial function and promoting tissue repair and anti-inflammatory effects. This mechanism is fundamentally different from estrogen-based treatments that directly target hormone receptors.

How Light Therapy Fits Into a Broader GSM Strategy

Managing GSM is not one-size-fits-all. A case-based review from the Mayo Clinic by Jyothsna Cyriac and Richa Sood emphasizes that treatment must account for a woman’s full health profile, including cancer history, cardiovascular risk, and personal comfort with different therapies.

The established first line for GSM remains low-dose vaginal estrogen, which is highly effective and has minimal systemic absorption. For women who cannot or prefer not to use estrogen, options include vaginal DHEA (prasterone), the selective estrogen receptor modulator ospemifene, and moisturizers or lubricants. The emergence of PBM introduces a new category: an energy-based, non-hormonal medical device.

It fills a particular gap for women seeking treatment for urinary incontinence, a symptom that can be more challenging to address with topical vaginal products alone. The trial’s finding that PBM improved dryness suggests it may support the vulvovaginal tissue’s overall health, similar to how it is used in wound healing and dermatology. Its limitation regarding sexual function indicates it is not a comprehensive solution for all GSM symptoms, at least with the current four-week protocol.

Building an Individualized Treatment Plan

Clinicians at specialized menopause clinics typically construct a plan by assessing symptom severity, patient preference, and medical history. The goal is sustained improvement, as GSM is a chronic condition of estrogen deficiency.

For a woman with mild dryness, a regular vaginal moisturizer might suffice. Another with a history of hormone-sensitive breast cancer may be steered toward non-hormonal options like laser therapy or ospemifene. A woman whose primary concern is stress urinary incontinence might find the new PBM data particularly relevant, while also considering pelvic floor physical therapy. Treatment can be layered; for example, a patient might use a vaginal moisturizer for daily comfort while undergoing a course of PBM for structural support.

It’s important to note that energy-based devices like lasers and radiofrequency for GSM have faced scrutiny regarding their long-term safety and efficacy data. The Pereira study is a step toward rigorous evidence for one specific type of energy therapy. More research with larger groups and longer follow-up periods, as the authors note, is needed to confirm durability and refine dosing.

Conclusion

The landscape for GSM treatment is becoming more nuanced, moving beyond hormones alone. Photobiomodulation represents a promising, non-invasive option backed by initial clinical data, particularly for urinary symptoms. Effective management requires a partnership with a knowledgeable provider to select from the growing array of tools available.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42060269/
https://pubmed.ncbi.nlm.nih.gov/41892504/